Resveratrol inhibits expression of EMMPRIN from macrophages

Yaoxue Xuebao

Volumn 41, Issue 7, 2006, Pages 625-630

  Ge, Heng ^a   Zhang, Jun Feng ^b   Guo, Bing Shi ^c   He, Ben ^a   Wang, Bin Yao ^a   Wang, Chang Qian ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

^c Shanghai Health Promotion Center   (China)

Author keywords

EMMPRIN; MMPs; Monocytes macrophages; PPAR ; Resveratrol

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; 2-CHLORO-5-NITROBENZANILIDE; ANILIDE; ANTINEOPLASTIC AGENT; CD147 ANTIGEN; GELATINASE B; HYBRID PROTEIN; LUCIFERASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; RESVERATROL; STILBENE DERIVATIVE;

ARTICLE; BIOSYNTHESIS; BREAST TUMOR; CELL DIFFERENTIATION; CELL LINE; CELL STRAIN U937; COCULTURE; CYTOLOGY; DOSE RESPONSE; DRUG EFFECT; FEMALE; GENETICS; HUMAN; MACROPHAGE; METABOLISM; MONOCYTE; PATHOLOGY; TUMOR CELL LINE; WESTERN BLOTTING;

ANILIDES; ANTIGENS, CD147; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL DIFFERENTIATION; CELL LINE; CELL LINE, TUMOR; COCULTURE TECHNIQUES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LUCIFERASES; MACROPHAGES; MATRIX METALLOPROTEINASE 9; MONOCYTES; PPAR GAMMA; RECOMBINANT FUSION PROTEINS; STILBENES; THIAZOLIDINEDIONES; U937 CELLS;

EID: 33748928003     PISSN: 05134870     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Ikeda U, Shimada K. Matrix metalloproteinases and coronary artery diseases [J]. Clin Cardiol, 2003, 26:55-59.
2. Zeng B, Prasan A, Fung KC, et al. Elevated circulating levels of matrix metalloproteinase-9 and -2 in patients with symptomatic coronary artery disease [J]. Int Med J, 2005, 35:331-335.
3. Chen F, Eriksson P, Hansson GK, et al. Expression of matrix metalloproteinase 9 and its regulators in the unstable coronary atherosclerotic plaque [J]. Int J Mol Med, 2005, 15:57-65.
4. Funayama H, Ishikawa SE, Kubo N, et al. Increases in interleukin-6 and matrix metalloproteinase-9 in the infarct-related coronary artery of acute myocardial infarction [J]. Circ J, 2004, 68:451-454.
5. Lee WH, Kim SH, Lee Y, et al. Tumor necrosis factor receptor superfamily 14 is involved in atherogenesis by inducing proinflammatory cytokines and matrix metalloproteinases [J]. Arterioscler Thromb Vasc Biol, 2001, 21:2004-2010.
6. Li R, Huang L, Guo H, et al. Basigin (murine EMMPRIN) stimulates matrix metalloproteinase production by fibroblasts [J]. J Cell Physiol, 2001, 186:371-379.
7. Tang Y, Kesavan P, Nakada MT, et al. Tumor-stroma interaction: positive feedback regulation of extracellular matrix metalloproteinase inducer (EMMPRIN) expression and matrix metalloproteinase-dependent generation of soluble EMMPRIN [J]. Mol Cancer Res, 2004, 2:73-80.
8. Major TC, Liang L, Lu X, et al. Extracellular matrix metalloproteinase inducer (EMMPRIN) is induced upon monocyte differentiation and is expressed in human atheroma [J]. Arterioscler Thromb Vasc Biol, 2002, 22:1200-1207.
9. Yoon YW, Kwon HM, Hwang KC, et al. Upstream regulation of matrix metalloproteinase by EMMPRIN; extracellular matrix metalloproteinase inducer in advanced atherosclerotic plaque [J]. Atherosclerosis, 2005, 180:37 -44.
10. Haug C, Lenz C, Diaz F, et al. Oxidized low-density lipoproteins stimulate extracellular matrix metalloproteinase inducer (EMMPRIN) release by coronary smooth muscle cells [J]. Arterioscler Thromb Vasc Biol, 2004, 24:37-44.
11. Zern TL, West KL, Fernandez ML, et al. Grape polyphenols decrease plasma triglycerides and cholesterol accumulation in the aorta of ovariectomized guinea pigs [J]. J Nutr, 2003, 133:2268-2272.
12. Imamura G, Bertelli AA, Bertelli A, et al. Pharmacological preconditioning with resveratrol: an insight with iNOS knockout mice [J]. Am J Physiol Heart Circ Physiol, 2002, 282:H1996-H2003.
13. Tsai SH, Lin-Shiau SY, Lin JK, et al. Suppression of nitric oxide synthase and the down-regulation of the activation of NFkappaB in macrophages by resveratrol [J]. Br J Pharmacol, 1999, 126:673-680.
14. Leiro J, Alvarez E, Arranz JA, et al. Effects of cis-resveratrol on inflammatory murine macrophages: antioxidant activity and down-regulation of inflammatory genes [J]. J Leukocyte Biol, 2004, 75:1156-1165.
15. Belguendouz L, Fremont L, Linard A. Resveratrol inhibits metal ion-dependent and independent peroxidation of porcine low-density lipoproteins [J]. Biochem Pharmacol, 1997, 53:1347-1355.
16. Reynolds M. Gainsharing: a cost-reduction strategy that may be back [J]. Healthc Financ Manage, 2002, 56:58-64.
17. Di Santo A, Mezzetti A, Napoleone E, et al. Resveratrol and quercetin down-regulate tissue factor expression by human stimulated vascular cells [J]. J Thromb Haemost, 2003, 1:1089-1095.
18. Li YT, Shen F, Bai JY, et al. Inhibition of dexamethasone, indomethacin and resveratrol on matrix metalloproteinase-9 and the mechanism of inhibition [J]. Acta Pharm Sin, 2003, 38:501-504.
19. Pasceri V, Wu HD, Willerson JT, et al. Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator activated receptor-gamma activators [J]. Circulation, 2000, 101:235-238.
20. Marx N, Sukhova G, Murphy C, et al. Macrophages in human atheroma contain PPAR gamma: differentiation-dependent peroxisomal proliferator-activated receptor gamma (PPAR gamma) expression and reduction of MMP-9 activity through PPAR gamma activation in mononuclear phagocytes in vitro [J]. Am J Pathol, 1998, 153:17-23.
21. Jiang C, Ting AT, Seed B, et al. PPAR-agonists inhibit production of monocyte inflammatory cytokines [J]. Nature, 1998, 391:82-86.